You are here

Eli Lilly

Lilly's lupus treatment succeeds in mid-stage trial

Lilly's lupus treatment succeeds in mid-stage trial

Reuters

clinical trials

Flag link:

Eli Lilly and AstraZeneca Drop PhIII Alzheimer's Candidate – BACE Class May Be Done

Eli Lilly and AstraZeneca Drop PhIII Alzheimer's Candidate – BACE Class May Be Done

CP Wire

Alzheimer's disease

BACE inhibitors

Flag link:

Eli Lilly and AstraZeneca Drop PhIII Alzheimer's Candidate – BACE Class May Be Done

Alzheimer's disease

Flag link:

Lilly's experimental colitis drug posts positive Phase 2 data

Lilly's experimental colitis drug posts positive Phase 2 data

Biopharma Dive

ulcerative colitis

monoclonal antibodies

Flag link:

Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning

Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning

Xconomy

rheumatoid arthritis

Flag link:

Novo Nordisk's oral diabetes drug beats Jardiance in study

Novo Nordisk's oral diabetes drug beats Jardiance in study

Yahoo/Reuters

Flag link:

Lilly's cancer business loses its chief just as it's leaning on oncology for growth

Lilly's cancer business loses its chief just as it's leaning on oncology for growth

Fierce Pharma

Flag link:

Alzheimer’s Disease: Companies Weigh Revised FDA Draft Guidance

Alzheimer’s Disease: Companies Weigh Revised FDA Draft Guidance

RAPS.org

Alzheimer's disease

Denali Therapeutics

Flag link:

Lilly's CGRP drug succeeds in 'worst kind of migraine'

Lilly's CGRP drug succeeds in 'worst kind of migraine'

Biopharma Dive

cluster headaches

Flag link:

Eli Lilly Bolsters Cancer Drug Pipeline with $110M Deal for AurKa

Eli Lilly Bolsters Cancer Drug Pipeline with $110M Deal for AurKa

Xconomy

Flag link:

Eli Lilly Takes $7M Gamble On Global Health Working... In Indiana

Eli Lilly Takes $7M Gamble On Global Health Working... In Indiana

Forbes

emerging markets

Flag link:

3 Biotech Stocks That Soared This Week

3 Biotech Stocks That Soared This Week

Motley Fool

ARMO BioSciences

Flag link:

Eight years after Eli Lilly dumped it, an upstart biotech has nabbed teplizumab and filed a $56M IPO to back a PhIII comeback

Eight years after Eli Lilly dumped it, an upstart biotech has nabbed teplizumab and filed a $56M IPO to back a PhIII comeback

Endpoints

Flag link:

Lilly Acquires Immuno-Oncology Asset With $1.6 Billion Purchase of ARMO BioSciences

Lilly Acquires Immuno-Oncology Asset With $1.6 Billion Purchase of ARMO BioSciences

CP Wire

ARMO BioSciences

immuno-oncology

Flag link:

Lilly Acquires Immuno-Oncology Asset With $1.6 Billion Purchase of ARMO BioSciences

ARMO BioSciences

Flag link:

Eli Lilly Shares Seen Rising 18% as Profits Surge

Eli Lilly Shares Seen Rising 18% as Profits Surge

Investopedia

Flag link:

Lilly, Pfizer, Sanofi lead in patent litigation, report says

Lilly, Pfizer, Sanofi lead in patent litigation, report says

Biopharma Dive

patent lawsuits

Flag link:

Express Scripts targets Amgen, Lilly migraine drugs in pricing shift

Express Scripts targets Amgen, Lilly migraine drugs in pricing shift

Reuters

Express Scripts

Flag link:

Lilly’s strong Q1 cushions the blow of FDA thumbs-down on high-dose baricitinib

Lilly’s strong Q1 cushions the blow of FDA thumbs-down on high-dose baricitinib

Fierce Pharma

Flag link:

FDA Panel Splits on Lilly Arthritis Drug, Backs Lower of Two Doses

FDA Panel Splits on Lilly Arthritis Drug, Backs Lower of Two Doses

Xconomy

advisory panels

rheumatoid arthritis

Flag link:

Pages